Advancing the fight against respiratory syncytial virus (RSV)

Pfizer is developing a potential vaccine to help protect people from RSV.

Respiratory syncytial virus (RSV) causes an infection that affects the lungs and airways. There is currently no effective treatment or vaccine for RSV infection. Each year, close to 180,000 older adults in the United States are hospitalized with RSV disease, and approximately 14,000 die. Children, particularly during infancy and up to age 5, are also heavily affected by RSV. Each year in the US, approximately 58,000 children are hospitalized, and RSV is the most common cause of pneumonia in children under a year of age.

Around the world, there is an urgent need for a vaccine that can prevent RSV. That’s why Pfizer is working to develop an RSV vaccine for adults, and for pregnant women to protect their infants.

Scientists have been trying to develop a vaccine for RSV for over half a century. Recent research has helped establish a better understanding of the virus. For example, we have learned how an important protein in the virus changes shape, and that the original shape (RSVpreF) causes a strong immune response. Pfizer has applied this scientific advance in its development of an investigational RSVpreF protein-based vaccine that is being studied in several clinical trials for adults ages 60 and over, as well as for expectant mothers in their second or third trimester.

If you or a loved one are considering taking part in one of Pfizer’s RSV vaccine clinical trials, find more information below.

Find a respiratory syncytial virus (RSV) clinical trial

Find a Pfizer clinical trial

Refine your search

Filter by

Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Indicates the current stage of a clinical study and whether it is or will be open for enrollment or in currently active and enrolling in the near future.
  • 50
  • 100
  • 150
  • 200
  • 250+

Searching for Matching Trials ...

  • Save search
  • Saved trials

Contact us

For more information about participation in a Pfizer clinical trial, please email or call the Pfizer Clinical Trial Contact Center at 1-800-887-7002.

We’re sorry, but we couldn’t find a match for your search.


  • Broaden your search by using fewer search terms or adjusting the selected filters
  • Check your spelling


  • This website only provides information about Pfizer clinical trials. To search for all registered clinical trials, regardless of the study sponsor, you may visit

About respiratory syncytial virus (RSV)

Respiratory syncytial virus is a highly contagious virus that affects the lungs and airways. The virus can spread through coughing or sneezing, by touching infected surfaces, and through direct contact with an infected person. Infections happen in people of all ages.

For most adults, infections feel like a common cold. But an infection can be life-threatening for infants, the elderly, and those with weak immune systems.

There is currently no effective treatment or vaccine for RSV. Seriously ill people needing RSV treatment receive oxygen and fluids to improve their symptoms.